Cargando…

Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report

To date, allogenic stem cell transplant (ASCT) remains the only potential curative option for patients with primary myelofibrosis (PMF). However, relapse rates and associated mortality remain a concern. A second ASCT may not be feasible due to advancing age, declined functional status, donor unavail...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Verna, Michelis, Fotios V., Sibai, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928792/
https://www.ncbi.nlm.nih.gov/pubmed/36819176
http://dx.doi.org/10.1002/jha2.611
_version_ 1784888717381468160
author Cheung, Verna
Michelis, Fotios V.
Sibai, Hassan
author_facet Cheung, Verna
Michelis, Fotios V.
Sibai, Hassan
author_sort Cheung, Verna
collection PubMed
description To date, allogenic stem cell transplant (ASCT) remains the only potential curative option for patients with primary myelofibrosis (PMF). However, relapse rates and associated mortality remain a concern. A second ASCT may not be feasible due to advancing age, declined functional status, donor unavailability, toxicities associated with a second ASCT. Herein, we report the first case of utilizing initially azacitidine and subsequently oral decitabine + cedazuridine (decitabine), in the context of relapsed PMF post‐ASCT. Utilizing both hypomethylating agents provided disease control and improved donor/myeloid lineage chimerism levels, and the patient also remained transfusion independent, with preserved functional status and quality of life.
format Online
Article
Text
id pubmed-9928792
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99287922023-02-16 Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report Cheung, Verna Michelis, Fotios V. Sibai, Hassan EJHaem Case Reports To date, allogenic stem cell transplant (ASCT) remains the only potential curative option for patients with primary myelofibrosis (PMF). However, relapse rates and associated mortality remain a concern. A second ASCT may not be feasible due to advancing age, declined functional status, donor unavailability, toxicities associated with a second ASCT. Herein, we report the first case of utilizing initially azacitidine and subsequently oral decitabine + cedazuridine (decitabine), in the context of relapsed PMF post‐ASCT. Utilizing both hypomethylating agents provided disease control and improved donor/myeloid lineage chimerism levels, and the patient also remained transfusion independent, with preserved functional status and quality of life. John Wiley and Sons Inc. 2022-11-16 /pmc/articles/PMC9928792/ /pubmed/36819176 http://dx.doi.org/10.1002/jha2.611 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Cheung, Verna
Michelis, Fotios V.
Sibai, Hassan
Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report
title Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report
title_full Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report
title_fullStr Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report
title_full_unstemmed Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report
title_short Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report
title_sort improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—first case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928792/
https://www.ncbi.nlm.nih.gov/pubmed/36819176
http://dx.doi.org/10.1002/jha2.611
work_keys_str_mv AT cheungverna improveddonorchimerisminrelapsemyelofibrosispostallogenicstemcelltransplantwithazacitidineandoraldecitabinefirstcasereport
AT michelisfotiosv improveddonorchimerisminrelapsemyelofibrosispostallogenicstemcelltransplantwithazacitidineandoraldecitabinefirstcasereport
AT sibaihassan improveddonorchimerisminrelapsemyelofibrosispostallogenicstemcelltransplantwithazacitidineandoraldecitabinefirstcasereport